MedTrace Logo

Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®

NCT01579695 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 391

Last updated 2018-09-11

No results posted yet for this study

Summary

The purpose of this observational, 10-year, prospective cohort study is to assess the potential safety concerns of long-term exposure to EGRIFTA® in HIV-infected subjects with abdominal lipohypertrophy compared with a similar group of subjects not exposed to EGRIFTA®.

Conditions

Interventions

DRUG

Tesamorelin for injection

Daily 2 mg subcutaneous injections of Tesamorelin

Sponsors & Collaborators

  • Theratechnologies

    lead INDUSTRY

Principal Investigators

  • Jean-Claude Mamputu, PhD · Theratechnologies Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2018-05-31
Completion
2018-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01579695 on ClinicalTrials.gov